1Hoste G, Vossaert K, Poppe WA. The clinical role of HPV testing in primary and secondary cervical cancer screening [J/ OL]. Obstet Gynecol Int, 2013, 2013:610373 [2015-11-03]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713364/pdf/ OGI2013-610373.pdf.
2Kajitani N, Satsuka A, Kawate A, et al. Productive lifecycle of human papillomaviruses that depends upon squamous epithelial differentiation [J/OL]. Front Microbiol, 2012, 3: 152 [2015-11-03]. http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3334820/pdf/fmicb-03-00152.pdf.
3Faridi R, Zahra A, Khan K, et al. Oncogenic potential of human papillomavirus (HPV) and its relation with cervical cancer [J/OL]. Virol J, 2011, 8:269 [2015-11-04]. http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC3118362/pdf/1743- 422X-8-269.pdf.
4Munoz N, Bosch FX, de Sanjos6 S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group [J]. N Engl J Med, 2003, 348(6): 518-527.
5Zappacosta R, Colasante A, Viola P, et al. Chromogenic in situ hybridization and p16/Ki67 dual staining on formalin- fixed paraffin-embedded cervical specimens: correlation with HPV-DNA test, E6/E7 mRNA test, and potential clinical applications [J/OL]. Biomed Res Int, 2013, 2013:453606 [2015-11-04]. http ://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3858005/pdf/BMRI2013-453606.pdf.
6Bernard X, Robinson P, Nomine Y, et al. Proteasomal degradation of p53 by human papillomavims E6 oncoprotein relies on the structural integrity of p53 core domain [J/ OL]. PLoS One, 2011, 6(10): e25981 [2015-11-07]. http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC3203139/pdf/ pone.0025981.pdf.
7Li W, Anderson RA. Star-PAP controls HPV E6 regulation of p53 and sensitizes cells to VP-16 [J]. Oncogene, 2014, 33(7): 928-932.
8Huh K, Zhou X, Hayakawa H, et al. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor [J]. J Virol, 2007, 81(18): 9737-9747.
9Agorastos T, Chatzigeorgiou K, Brotherton JM, et al. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far [J]. Vaccine, 2009, 27(52): 7270-7281.
10Van Damme P, Olsson SE, Block S, et al. Immunogenicity and safety of a 9-valent HPV vaccine [J]. Pediatrics, 2015, 136(1): e28-e39.
